FDA rejects Teva’s high-potency biosimilar of Humira again
After a record run, fewer biotechs are going public
Sarepta shares drop as report says FDA almost rejected under-review gene therapy
Medtech sector poised for growth as healthcare staffing tops pre-COVID levels
*please scroll down for all the latest news*
